Home Metabolism phosphatase inhibitor Batoprotafib(TNO155) For research use only.

Batoprotafib(TNO155)

Batoprotafib(TNO155) is an inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2 /src homology region 2 domain phosphatase /PTPN11) with IC50 of 0.011 µM. TNO155 has potential antineoplastic activity.

Batoprotafib(TNO155) Chemical Structure

Batoprotafib(TNO155) Chemical Structure

CAS No. 1801765-04-7

Purity & Quality Control

Batch: S898701 DMSO]84 mg/mL]false]Ethanol]5 mg/mL]false]Water]Insoluble]false Purity: 99.44%
99.44

Batoprotafib(TNO155) Related Products

Biological Activity

Description Batoprotafib(TNO155) is an inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2 /src homology region 2 domain phosphatase /PTPN11) with IC50 of 0.011 µM. TNO155 has potential antineoplastic activity.
Targets
SHP-2 [1]
(Cell-free assay)
0.011 μM
In vitro
In vitro

TNO155 inhibits KYSE520 pERK and KYSE520 5-day cell proliferation with IC50 of 0.008 µM and of 0.100 µM, respectively. The off-target IC50 are 18 µM, 6.9 µM, 11 µM and > 30μM for Cav1.2, VMAT, SST3 and all others, respectively.[1]
Cell Research Cell lines PC-14 cells
Concentrations 3 μM
Incubation Time 24 h
Method

PC-14 cells were treated with nazartinib (0.1 or 0.3 µM), 3 µM TNO155, or the combination of nazartinib and TNO155 for 4 hours or 24 hours.
In Vivo
In vivo

TNO155 is a potent and selective first-in-class inhibitor of wild-type SHP2, with high oral bioavailability and BCS class I properties. The oral bioavailability of TNO155 in mouse, rat and money are 78%, 86%, and 60%, respectively.[1]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05541159 Withdrawn
Renal Impairment
Novartis Pharmaceuticals|Pharmaceutical Research Associates|Novartis
 March 19 2025 Phase 1
NCT05490030 Withdrawn
Hepatic Impairment
Novartis Pharmaceuticals|Pharmaceutical Research Associates|Novartis
 March 6 2025 Phase 1
NCT04330664 Active not recruiting
Advanced Cancer|Metastatic Cancer|Malignant Neoplastic Disease
Mirati Therapeutics Inc.|Novartis
 April 22 2020 Phase 1|Phase 2

Chemical Information & Solubility

Molecular Weight 421.95 Formula

C18H24ClN7OS
CAS No. 1801765-04-7 SDF --
Density g/mL
Smiles CC1C(C2(CCN(CC2)C3=CN=C(C(=N3)N)SC4=C(C(=NC=C4)N)Cl)CO1)N
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 84 mg/mL ( (199.07 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Batoprotafib(TNO155) | Batoprotafib(TNO155) supplier | purchase Batoprotafib(TNO155) | Batoprotafib(TNO155) cost | Batoprotafib(TNO155) manufacturer | order Batoprotafib(TNO155) | Batoprotafib(TNO155) distributor